ArticleScientific reports2025
Screening and evaluation of specific blood MiRNAs as potential biomarkers in diagnostics of gastric Cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Serum Aberrant Expression of miR-431-5p and Their Diagnostic Value in Parkinson's Disease.Neurochemical research · 2026Article
- Glioma identification from microRNA biomarkers using machine learning.Frontiers in systems biology · 2026Article
- Extracellular vesicle-enclosed microRNAs serve as non-invasive biomarkers in the major upper and lower gastrointestinal tract tumors: a bibliometric analysis (2010-2025).Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
To provide a novel direction for the diagnosis of gastric cancer (GC). The differentially expressed blood microRNAs (miRNAs) in gastric carcinoma were screened through SangerBox using the datasets GSE113486, GSE112264, and GSE113740. The miRNA-target genes prediction, conduct Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses were performed with the Database for Annotation, Visualization and Integrated Discovery (DAVID) 6.8. STRING analysis was further investigated with Cytoscape. The correlations among the expression levels of key miRNAs and prognosis/diagnostic value in GC patients were determined by survival prognosis and Receiver Operating Characteristic (ROC) curve analysis. Quantitative Reverse Transcription Polymerase Chain Reaction (RT-qPCR) was employed to detect the different expression levels of key miRNAs in human blood samples. In the process, the influence of Helicobacter pylori (H. pylori) infection on expression levels of miRNAs was analyzed with Gene Expression Omnibus 2R (GEO2R) in dataset GSE108307. To evaluate these findings, the expression level of Cytotoxin-associated gene A (CagA), along with clinical markers used in the help of GC pathologic diagnosis, were measured and compared with the key miRNAs obtained in this study. The bioinformatics analysis identified five crucial blood miRNAs, including hsa-miR-124-3p, hsa-miR-125a-3p, hsa-miR-29b-3p, hsa-miR-4276, and hsa-miR-575. The detection in human blood samples combined with cross-analysis involving H. pylori infection, the expression levels of CagA and clinical markers underscored the significance and effectiveness of these specific miRNAs in early diagnosis and monitoring of gastric carcinoma. This study identified five potential blood miRNA biomarkers for GC through bioinformatics analysis coupled with detection in human blood samples, thus providing new possibilities for important biomarkers related to diagnosis and prognosis of GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.